Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.

Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2012 Apr 1;18(7):2024-31. doi: 10.1158/1078-0432.CCR-11-2139. Epub 2012 Feb 14.

2.

FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2009 Apr 15;15(8):2856-63. doi: 10.1158/1078-0432.CCR-08-2537. Epub 2009 Apr 7.

3.

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.

Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC.

Cancer. 2012 Jun 15;118(12):3135-44. doi: 10.1002/cncr.26630. Epub 2011 Oct 21.

4.

Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.

Eary JF, Conrad EU, O'Sullivan J, Hawkins DS, Schuetze SM, O'Sullivan F.

J Bone Joint Surg Am. 2014 Jan 15;96(2):152-8. doi: 10.2106/JBJS.M.00062.

5.

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.

Gillies RS, Middleton MR, Han C, Marshall RE, Maynard ND, Bradley KM, Gleeson FV.

Br J Surg. 2012 Feb;99(2):239-45.

PMID:
22329010
6.

Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.

Weber MA, Bender K, von Gall CC, Stange A, Grünberg K, Ott K, Haberkorn U, Kauczor HU, Zechmann C.

J Gastrointestin Liver Dis. 2013 Mar;22(1):45-52.

7.

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.

Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16.

PMID:
24841218
8.

PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma.

Fendler WP, Lehmann M, Todica A, Herrmann K, Knösel T, Angele MK, Dürr HR, Rauch J, Bartenstein P, Cyran CC, Hacker M, Lindner LH.

J Nucl Med. 2015 Apr;56(4):530-7. doi: 10.2967/jnumed.114.152462. Epub 2015 Feb 26.

9.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
10.

Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.

Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth C, Büchler MW.

Ann Surg. 2005 Feb;241(2):286-94.

11.

Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.

García Vicente AM, Cruz Mora MÁ, León Martín AA, Muñoz Sánchez Mdel M, Relea Calatayud F, Van Gómez López O, Espinosa Aunión R, Gonzalez Ageitos A, Soriano Castrejón A.

Tumour Biol. 2014 Nov;35(11):11613-20. doi: 10.1007/s13277-014-2495-7. Epub 2014 Aug 20.

PMID:
25139100
12.

Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma.

Andersen KF, Fuglo HM, Rasmussen SH, Petersen MM, Loft A.

Medicine (Baltimore). 2015 Dec;94(51):e2319. doi: 10.1097/MD.0000000000002319.

13.

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.

Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J.

Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9.

PMID:
20617404
14.

Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):691-8. doi: 10.1007/s00259-009-1291-x. Epub 2009 Nov 14.

15.

Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.

Andreou D, Boldt H, Pink D, Jobke B, Werner M, Schuler M, Reichardt P, Tunn PU.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1076-83. doi: 10.1007/s00259-013-2680-8. Epub 2014 Feb 12.

PMID:
24519553
16.

Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?

Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ.

BMC Cancer. 2014 Jan 15;14:23. doi: 10.1186/1471-2407-14-23.

17.

Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.

Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC.

Clin Cancer Res. 2008 Feb 1;14(3):715-20. doi: 10.1158/1078-0432.CCR-07-1762.

18.

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M.

J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13.

19.

18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.

Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA.

Eur J Cancer. 2015 Nov;51(17):2545-52. doi: 10.1016/j.ejca.2015.07.044. Epub 2015 Aug 28.

20.

Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.

Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P.

Ann Oncol. 2012 Jul;23(7):1687-93. doi: 10.1093/annonc/mdr554. Epub 2011 Nov 23.

PMID:
22112970

Supplemental Content

Support Center